|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.07 / 6.19|
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
With earnings that lack much optimism, CSX not a good bet for buying on weakness now.
BMY is not 'out of the woods' yet, but aggressive traders could probe the long side here.
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.
One of pharma's biggest CEO's talks M&A action on the exchange.
These names are showing technical characteristics of either bullish or bearish reversal patterns.
I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.
Teva and Mallinckrodt both lost over 50% of their value in 2017 and might catch some momentum here.
Wall Street couldn't extend a record-breaking steak into a third session following the weekend terror attack in London.
Shares of drug maker Mallinckrodt were falling Wednesday afternoon
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I want to spend some time with my family right after the close. So let's move...
Shares of Mallinckrodt were lower on Tuesday, despite posting better than expected fourth-quarter revenue and profits.
These stocks are down some 20% over the last 30 months and look ripe for a rise.
Andrew Left says cracking down on Big Pharma may be all that Hillary Clinton and Donald Trump have in common.
Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
The drugmaker could be at risk as regulators begin to crack down on price hikes, Andrew Left says.
The drug that's helping boost the company's stock could become its biggest risk.
Markets were falling as oil prices continued their two-month descent below $40 a barrel.
Optimism that the United Kingdom will remain part of the EU was tempered by falling oil prices.
A rally above $65 with strong volume is needed to change the direction of MNK.
Stalking Mallinckrodt for a short and Alcoa for a buy as well.